Skip To Main Content
Kara Lombardo on Muck Rack

Kara Lombardo

As seen in: Nature, Wiley Online Library, BioRxiv, Cell Press, European Urology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kara

Contact Kara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Retraction Note: Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer

|
By Alok Singh, Monali Praharaj, Kara Lombardo, Takahiro Yoshida, Andres Matoso, Alex Baras, Liang Zhao, Geetha Srikrishna, Joy Huang, Pankaj Prasad Verified, Jonathan Powell, Max Kates, David J. McConkey, Drew Pardoll, William R Bishai, Trinity J. Bivalacqua
| Nature Verified
Retraction to: Nature Communications https://doi.org/10.1038/s41467-022-28509-z, published online 15 February 2022 The authors have retracted this article because there are duplicate cells in the Source Data for the following figure panels: Figure 1 panels d and e, Figure 2 panels a,b c and h, Figure 3 panels c and d, Figure 5 panel b, Figure 6 panels b and c, Figure 7 panels b, c and d, Figure S2 panels b, c and d, Figure S3 panel b, Figure S12, Figure S13 panels b, d and e, Figure S14...
Open in Who Shared View Duplicates (3) Issue with article?

WITHDRAWN: Recombinant BCG overexpressing a STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder

|
By Alok Singh, Monali Praharaj, Kara Lombardo, Takahiro Yoshida
| BioRxiv
Abstract The authors have withdrawn their manuscript owing to irregularities in the Source Data supporting some figures. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding authors. Competing Interest Statement WRB and TJB are co-founders of OncoSTING, LLC which holds rights to commercialize BCG-disA-OE.
Open in Who Shared Issue with article?

Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist

|
By Peter K. Um, Kara Lombardo, Takahiro Yoshida, Monali Praharaj
| BioRxiv
Abstract Despite the introduction of several new agents for the treatment of bladder cancer (BC), intravesical BCG remains a first line agent for the management of non-muscle invasive bladder cancer. In this study we evaluated the antitumor efficacy in animal models of BC of a recombinant BCG known as BCG-disA-OE that releases the small molecule STING agonist c-di-AMP.
Open in Who Shared Issue with article?
See all 6 articles